Pulmonary sarcoidosis: New genetic clues and ongoing treatment controversies

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 2, 2004, Pages 88-106

  Culver, Daniel A ^a   Thomassen, Mary Jane ^a   Kavuru, Mani S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHEMOKINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; HLA ANTIGEN; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; PENTOXIFYLLINE; T LYMPHOCYTE RECEPTOR; THALIDOMIDE; THALLIUM;

AFRICAN AMERICAN; ASTHMA; BORRELIA BURGDORFERI; CAUCASIAN; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAPHY; ENVIRONMENTAL FACTOR; EYE DISEASE; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HEART DISEASE; HEART MUSCLE BIOPSY; HEART SCINTISCANNING; HEREDITY; HOLTER MONITORING; HUMAN; KIDNEY DISEASE; LIVER BIOPSY; LIVER DISEASE; LUMBAR PUNCTURE; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; MYCOBACTERIUM; MYCOPLASMA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROPIONIBACTERIUM; RACE DIFFERENCE; RELAPSE; RETICULOENDOTHELIAL SYSTEM; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN DISEASE; THORAX RADIOGRAPHY; TIME; TROPHERYMA WHIPPELII; UNITED STATES;

EID: 1342268334     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.2.88     Document Type: Review

References (85)

1. Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev 1983; 5:124-56.
2. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG joint statement on sarcoidosis. Am J Respir Crit Care Med 1999; 160:736-755.
3. Rybicki BA, Major M, Popovich J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145:234-241.
4. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885-1889.
5. Keller AZ. Hospital, age, racial, occupational, geographical, clinical and survivorship characteristics in the epidemiology of sarcoidosis. Am J Epidemiol 1971; 94:222-230.
6. Hills SE, Parkes SA, Baker SB. Epidemiology of sarcoidosis in the Isle of Man-2: evidence for space-time clustering. Thorax 1987; 42:427-430.
7. Edmondstone WM. Sarcoidosis in nurses: is there an association? Thorax 1988; 43:342-343.
8. Kern DC, Neill MA, Wrenn DS, Varone JC. Investigation of a unique time-space cluster of sarcoidosis in firefighters. Am Rev Respir Dis 1993; 148:974-980.
9. Badrinas F, Morera J, Fite E, Plasencia A. Seasonal clustering of sarcoidosis [letter]. Lancet 1989; 2:455-456.
10. Burke WMJ, Keogh A, Maloney PJ, Delprado W, Bryant DH, Spratt P. Transmission of sarcoidosis via cardiac transplantation. Lancet 1990; 336:1579.
11. Heyll A, Meckenstock G, Aul C, et al. Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14:161-164.
12. Nunley DR, Hattler B, Keenan RJ, et al. Lung transplantation for end-stage pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:93-100.
13. Munro CS, Mitchell DN, Poulter LW, Cole PJ. Early cellular responses to intradermal injection of Kveim suspension in normal subjects and those with sarcoidosis. J Clin Pathol 1986; 39:176-182.
14. Mangiapan G, Hance AJ. Mycobacteria and sarcoidosis: an overview and summary of recent molecular biological data. Sarcoidosis 1995; 12:20-37.
15. Ishige I, Usui Y, Takemura T, Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 1999; 354:120-123.
16. Mandel J, Weinberger SE. Clinical insights and basic science correlates in sarcoidosis. Am J Med Sci 2001; 321:99-107.
17. James DG. Epidemiology of sarcoidosis. Sarcoidosis 1992; 9:79-87.
18. Rybicki BA, Maliarik MJ, Major M, Popovich J, Iannuzzi MC. Genetics of sarcoidosis. Clin Chest Med 1997; 18:707-717.
19. Ricker W, Clark M. Sarcoidosis: a clinicopathologic review of three hundred cases, including twenty-two autopsies. Am J Clin Pathol 1949; 19:725-749.
20. Scadding JG, Beresford OD, Sutherland I, Leckie WJH, Chappell AG. Familial associations in sarcoidosis. Tubercle 1973; 54:87-98.
21. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164:2085-2091.
22. Khoury MJ, Beaty TH, Liang KY. Can familial aggregation of disease be explained by familial aggregation of environmental risk factors? Am J Epidemiol 1988; 127:674-683.
23. Martinetti M, Tinelli C, Kolek V, et al. "The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995: 152:557-564.
24. Luisetti M, Beretta A, Casali L. Genetic aspects in sarcoidosis. Eur Respir J 2000; 16:768-780.
25. Schurmann M, Lympany PA, Reichel P, et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med 2000; 162:861-864.
26. Bianco A, Spiteri MA. Peripheral anergy and local immune hyperactivation in sarcoidosis: a paradox or birds of a feather. Clin Exp Immunol 1997; 110:1-3.
27. Rosen Y, Athanassiades TJ, Moon S, Lyons HA. Nongranulomatous interstitial pneumonitis in sarcoidosis: relationship to the development of epithelioid granulomas. Chest 1978; 74:122-125.
28. Goldstein RA, Janicki BW, Mirro J, Foellmer JW. Cell-mediated immune responses in sarcoidosis. Am Rev Respir Dis 1978; 117:55-62.
29. Kataria YP, Holter JF. Immunology of sarcoidosis. Clin Chest Med 1997; 18:719-739.
30. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224-1234.
31. Mana J, Gomez-Vaquero C, Montero A, et al. Löfgren's syndrome revisited: a study of 186 patients. Am J Med 1999; 107:240-245.
32. Ohara K, Okubo A, Kamata K, Sasaki H, Kobayashi J, Kitamura S. Transbronchial lung biopsy in the diagnosis of suspected ocular sarcoidosis. Arch Ophthalmol 1993; 111:642-644.
33. Lynch JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997; 18:755-785.
34. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest 2001; 120:881-886.
35. Stjernberg N, Björnstad-Pettersen H, Truedsson H. Flexible fiberoptic bronchoscopy in sarcoidosis. Acta Med Scand 1980; 208:397-399.
36. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58:1204-1211.
37. Perry A, Vuitch F. Causes of death in patients with sarcoidosis: a morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995; 119:167-172.
38. Shammas RL, Movahed A. Sarcoidosis of the heart. Clin Cardiol 1993; 16:462-472.
39. Tellier P, Paycha F, Antony I, et al. Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. Am J Med 1988; 85:189-193.
40. Kinney EL, Caldwell JW. Do thallium myocardial perfusion scan abnormalities predict survival in sarcoid patients without cardiac symptoms? Angiology 1990; 41:573-576.
41. Eguchi M, Tsuchihashi K, Hotta D, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology 2000; 94:193-199.
42. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DPTA-enhanced magnetic resonance imaging. Am J Med 2001; 110:520-527.
43. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999; 138:299-302.
44. Vatti R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:73-76.
45. Lynch JP, Sharma OP, Baughman RP. Extrapulmonary sarcoidosis. Semin Respir Infect 1998; 13:229-254.
46. Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis: clinico-pathologic features in 100 patients. Am J Surg Pathol 1993; 17:1272-1280.
47. Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57:847-852.
48. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157:1864-1868.
49. Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurologic manifestations. Arch Neurol 1985; 42:909-917.
50. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis-diagnosis and management. Q J Med 1999; 92:103-117.
51. Scott TF. Neurosarcoidosis: progress and clinical aspects. Neurology 1993; 43:8-12.
52. Dumas JL, Valeyre D, Chapelon-Abric C, et al. Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy. Radiology 2000; 214:411-420.
53. Sharma OP. Cutaneous sarcoidosis: clinical features and management. Chest 1972; 61:320-325.
54. Goldstein RA, Israel HL, Becker KL, Moore CF. The infrequency of hypercalcemia in sarcoidosis. Am J Med 1971; 51:21-30.
55. Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest 1996; 109:535-539.
56. Adams JS, Sharma OP, Diz MM, Endres DB. Ketoconazole decreases the 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab 1990; 70:1090-1095.
57. O'Leary TJ, Jones G, Yip A, Lohnes D, Cohanim M, Yendt E. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 1986; 315:727-730.
58. Kataria YP, Whitcomb ME. Splenomegaly in sarcoidosis. Arch Intern Med 1980; 140:35-37.
59. Leonard C, Tormey VJ, O'Keane C, Burke CM. Bronchoscopic diagnosis of sarcoidosis. Eur Respir J 1997; 10:2722-2724.
60. Turner-Warwick M, McAllister W, Lawrence R, Britten A, Haslam PL. Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management? Thorax 1986; 41:903-913.
61. Laviolette M, LaForge J, Tennina S, Boulet LP. Prognostic value of bronchoalveolar lavage lymphocyte count in recently diagnosed pulmonary sarcoidosis. Chest 1991; 100:380-384.
62. Munck A, Mendel DB, Smith LI, Orti E. Glucocorticoid receptors and actions. Am Rev Respir Dis 1990; 141:S2-S10.
63. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids. Chest 1999; 115:1158-1165.
64. Du Bois RM. Corticosteroids in sarcoidosis: friend or foe? Eur Respir J 1994; 7:1203-1209.
65. Israel HL. Corticosteroid treatment of sarcoidosis - who needs it? N Y State J Med 1987; 87:490.
66. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51:238-247.
67. Harkleroad LE, Young RL, Savage PJ, Jenkins DW, Lordon RE. Pulmonary sarcoidosis: long-term follow-up of the effects of steroid therapy. Chest 1982; 82:84-87.
68. Pietinalho A, Tukiainen P, Haahtela T, et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121:24-31.
69. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149:893-898.
70. Spratling L, Tenholder MF, Underwood GH, Feaster BL, Requa RK. Daily versus alternate day prednisone therapy for stage II sarcoidosis. Chest 1985; 88:687-690.
71. James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet 1967; 2:625-628.
72. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest 1997; 111:623-631.
73. Eule H, Weinecke A, Roth I. The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Ann NY Acad Sci 1986; 465:695-701.
74. Johns CJ, Schonfeld SA, Scott PP, et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroids. Ann NY Acad Sci 1986; 465:702-712.
75. Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993; 10:56-61.
76. Alberts C, van der Mark TW, Jansen HM, et al. Inhaled budesonide in pulmonary sarcoidosis: a double-blind placebo-controlled study. Eur Respir J 1995; 8:682-688.
77. DuBois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TAJ. Randomized trial of inhaled fluticasone in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13:1345-1350.
78. Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236:285-290.
79. Pacheco Y, Marechal C, Marechal F, Biot N, Perrin Fayolle M. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis 1985; 2:107-113.
80. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double-blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:60-66.
81. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160:192-197.
82. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155:1665-1669.
83. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:70-74.
84. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32:866-869.
85. Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med 1997; 156:1371-1376.